The core activity of Cellis is the development of cell-based cancer treatments, in particular through the application of a platform technology that enables targeted delivery of active substances directly into cancer cells and modifies the tumor microenvironment to inhibit the growth of cancer cells.
AI-generated
Offering
Products & services
Industry:Medical Technology IndustryPharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Cell-based oncology therapy for solid tumors, centered on macrophage drug conjugates, targeted delivery of active compounds, and development toward clinical trials.
Macrophage-Drug Conjugate (MDC) technology
Macrophage-drug conjugate platform for solid tumors, using macrophages loaded with ferritin-drug complexes to deliver immunomodulators, inhibitors, cytotoxic drugs, radioisotopes or peptides.
Preclinical research and development
Preclinical research on MDC technology, validation in cell and animal models, TRAIN mechanism of action, tumour penetration, drug release, and safety in solid tumors.
Development of cell therapies for solid tumors
Development of allogeneic, ready-to-use cell therapies for glioblastoma, ovarian cancer, pancreatic cancer, head and neck cancer and other solid tumors.
Clinical development of MDC-735
Preparation and clinical development of the MDC-735 therapy, including GMP manufacturing, regulatory submission documents and Phase I studies for solid tumors.
Knowledge
No knowledge articles yet
Once Cellis AG has claimed this profile, we'll publish editorial articles and case studies here together.